{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:02Z","timestamp":1777934702957,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Traditionally, intramuscular (IM) injections have been avoided in patients with haematological diseases due to the risk of iatrogenic haematoma. Tixagevimab-cilgavimab (Evusheld\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) is a novel monoclonal antibody combination used as preexposure prophylaxis against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for those at highest risk of severe infections. It is delivered as two separate IM injections (1.5 mL each). Patients with haematological disease are at higher risk for severe SARS-CoV-2 infections, which may be partially abrogated by the prophylactic inoculation of tixagevimab-cilgavimab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A combined retrospective and prospective study of patients under the haematology service at a large metropolitan hospital receiving tixagevimab-cilgavimab was conducted. Tixagevimab-cilgavimab was administered IM to all patients, with platelet and factor replacement provided according to local protocols. Patients completed a numerical pain score daily for seven days following the injection, with scores \u22654\/10 prompting an ultrasound to identify iatrogenic gluteal haematomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study recruited 131 patients; 66 patients were thrombocytopenic, including 10 patients with a platelet count &lt;30\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L. Fourteen patients (10.7%) received a single platelet transfusion prior to tixagevimab-cilgavimab administration, while two patients received fresh frozen plasma. No gluteal haematomas were identified, and only two patients reported an initial pain score of \u22654\/10.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The intramuscular administration of tixagevimab-cilgavimab in patients with haematological diseases was well tolerated and was not associated with iatrogenic haematoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241284944","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T15:10:40Z","timestamp":1726585840000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of intramuscular tixagevimab-cilgavimab (Evusheld\n                    <sup>\u00ae<\/sup>\n                    ) administration in patients at risk of iatrogenic haematoma due to haematological disorders"],"prefix":"10.1177","volume":"32","author":[{"given":"Jacques A. J.","family":"Malherbe","sequence":"first","affiliation":[{"name":"Fiona Stanley Hospital"},{"name":"University of Western Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-2683","authenticated-orcid":false,"given":"Jeanie","family":"Misko","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishani K.","family":"Jayawardena","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D. M.","family":"Rawlins","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurens","family":"Manning","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital"},{"name":"School of Medicine, University of Western Australia, Crawley WA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Purtill","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital"},{"name":"PathWest Laboratory Medicine WA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50607"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116620"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.07.015"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.12.018"},{"key":"e_1_3_3_6_2","first-page":"32","article-title":"Large-volume IM injections: a review of best practices","volume":"2013","author":"Hopkins U","year":"2013","unstructured":"Hopkins U, Arias CY. Large-volume IM injections: a review of best practices. Oncol Nurs Advisor 2013; 2013: 32\u201337.","journal-title":"Oncol Nurs Advisor"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000368058.72729.c6"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-015-1275-8"},{"key":"e_1_3_3_9_2","first-page":"13","article-title":"Spontaneous muscle haematomas: management of 10 cases","volume":"10","author":"Palatucci V","year":"2014","unstructured":"Palatucci V, Lombardi G, Lombardi L, et al. Spontaneous muscle haematomas: management of 10 cases. Transl Med 2014; 10: 13\u201317.","journal-title":"Transl Med"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.35827\/cp.2021.20.1.43"},{"key":"e_1_3_3_11_2","article-title":"Intramuscular hematoma with motor weakness after trigger point injection","volume":"96","author":"Kim SG","year":"2017","unstructured":"Kim SG, Shim KS, Lee DW, et al. Intramuscular hematoma with motor weakness after trigger point injection. Medicine (Baltimore) 2017; 96: e8135.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40278-015-6937-9"},{"key":"e_1_3_3_13_2","first-page":"223","article-title":"Two patients with acute thrombocytopenia following gold administration and five-year follow-up","volume":"61","author":"Levin MD","year":"2003","unstructured":"Levin MD, van\u2018t Veer MB, de Veld JC, et al. Two patients with acute thrombocytopenia following gold administration and five-year follow-up. J Med 2003; 61: 223\u2013225.","journal-title":"J Med"},{"key":"e_1_3_3_14_2","article-title":"Intramuscular injection safety without aspiration in the ventro-gluteal region during vaccination: randomized clinical trial","volume":"75","author":"da Albuquerque da Silva AMO","year":"2022","unstructured":"da Albuquerque da Silva AMO, Santos RCS, Araujo MGS, et al. Intramuscular injection safety without aspiration in the ventro-gluteal region during vaccination: randomized clinical trial. Rev Bras Enferm 2022; 75: e20201119.","journal-title":"Rev Bras Enferm"},{"key":"e_1_3_3_15_2","first-page":"1","article-title":"Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial","volume":"8","author":"Casajuana J","year":"2008","unstructured":"Casajuana J, Iglesias B, Fabregas M, et al. Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial. BMC Blood Disord 2008; 8: 1.","journal-title":"BMC Blood Disord"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2017.06.002"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(98)80023-1"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-019-02013-6"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/PEC.0b013e31827b2299"},{"key":"e_1_3_3_20_2","unstructured":"AstraZeneca Pty Ltd. Australian product information Evusheld (tixagevimab and cilgavimab). https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2022-PI-01156-1&d=20221109172310101 (9 November 2022)."},{"key":"e_1_3_3_21_2","unstructured":"AstraZeneca Pharmaceuticals LP. Fact sheet for healthcare providers: emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab). https:\/\/www.fda.gov\/media\/154701\/download (9 November 2022)."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(00)29025-0"},{"key":"e_1_3_3_23_2","first-page":"441","article-title":"Pain and hyperalgesia in osteoarthritis of the hands","volume":"27","author":"Farrell M","year":"2000","unstructured":"Farrell M, Gibson S, McMeeken J, et al. Pain and hyperalgesia in osteoarthritis of the hands. J Rheumatol 2000; 27: 441\u2013447.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/jpmn.2000.9759"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(96)02996-X"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241284944","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241284944","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241284944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:22Z","timestamp":1777689022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241284944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/10781552241284944"],"URL":"https:\/\/doi.org\/10.1177\/10781552241284944","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]}}}